THU0392 Efficacy and Safety of Belimumab Given for 12 Months in Primary sjögren's Syndrome: The Beliss Open-Label Phase II Study

S. De Vita; L. Quartuccio; R. Seror; S. Salvin; P. Ravaud; M. Fabris; G. Nocturne; S. Gandolfo; M. Isola; X. Mariette

doi:10.1136/annrheumdis-2015-eular.3101

Article info

Poster Presentations

SLE, Sjögren's and APS - treatment

THU0392 Efficacy and Safety of Belimumab Given for 12 Months in Primary sjögren's Syndrome: The Beliss Open-Label Phase II Study

Authors

S. De Vita 1Department of Medical and Biological Sciences, Rheumatology Clinic, University Hospital of Udine, Udine, Italy PubMed articles Google scholar articles
L. Quartuccio 1Department of Medical and Biological Sciences, Rheumatology Clinic, University Hospital of Udine, Udine, Italy PubMed articles Google scholar articles
R. Seror 2Université Paris-Sud, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Paris-Sud, INSERM U1012, Le Kremlin Bicêtre, Paris, France PubMed articles Google scholar articles
S. Salvin 3Rheumatology Clinic, University Hospital of Udine, Udine, Italy PubMed articles Google scholar articles
P. Ravaud 4AP-HP, Hôtel Dieu Hospital, Centre of Clinical Epidemiology, INSERM, U738, University of Paris Descartes, Faculty of Medicine, Paris, France PubMed articles Google scholar articles
M. Fabris 5Institute of Pathology, University Hospital of Udine PubMed articles Google scholar articles
G. Nocturne 2Université Paris-Sud, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Paris-Sud, INSERM U1012, Le Kremlin Bicêtre, Paris, France PubMed articles Google scholar articles
S. Gandolfo 3Rheumatology Clinic, University Hospital of Udine, Udine, Italy PubMed articles Google scholar articles
M. Isola 6Department of Medical and Biological Sciences, Institute of Statistics, Udine, Italy PubMed articles Google scholar articles
X. Mariette 2Université Paris-Sud, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Paris-Sud, INSERM U1012, Le Kremlin Bicêtre, Paris, France PubMed articles Google scholar articles

Citation

De Vita S, Quartuccio L, Seror R, et al

THU0392 Efficacy and Safety of Belimumab Given for 12 Months in Primary sjögren's Syndrome: The Beliss Open-Label Phase II Study

Annals of the Rheumatic Diseases 2015;74:338-339.

Publication history

First published June 9, 2015.

Online issue publication

April 13, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password